
News|Articles|September 1, 2006
First-time generic approvals (September 2006)
Azithromycin for oral suspension, 100 mg/5 mL and 200 mg/5 mL (equiv to Zithromax for oral suspension)
Advertisement
Azithromycin for oral suspension, 100 mg/5 mL and 200 mg/5 mL (equiv to Zithromax for oral suspension)
PLIVA
Meloxicam tablets, 7.5 and 15 mg (equiv to Mobic tablets)
BRECKENRIDGE, COREPHARMA, CARACO, LUPIN LIMITED, MYLAN, WATSON, ZYDUS, ROXANE, TEVA, GLENMARK, PAR, MUTUAL, ACTAVIS TOTOWA, GENPHARM
Estradiol transdermal system, 0.0375 mg/24 hours and 0.06 mg/24 hours (equiv to Climara transdermal system)
MYLAN
Metoprolol extended-release tablets, 25 mg (equiv to Toprol-XL extended-release tablets)
SANDOZ
Advertisement
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
USPS Woes Continue: Health Plans, Be Prepared
2
Updated: FDA approves first-in-class therapy for metastatic pancreatic cancer
3
FDA approves Tevimbra and Ziihera for HER2-positive gastroesophageal cancer
4
AI-assisted nodule detection could boost early lung cancer diagnosis
5























